Weight was examined within a cardiovascular program
This prespecified SELECT analysis assessed weight and body-size measurements in adults with established cardiovascular disease and overweight or obesity, without diabetes. The parent trial randomized 17,604 participants to semaglutide or placebo. The weight analysis reported outcomes through 208 weeks, extending the evidence window to four years. [1]
The parent trial’s purpose and population help explain why this report should not be read as just another version of a short weight-management study. Participants entered a cardiovascular-outcomes program. The context remains relevant even when a secondary paper places weight at the center of its title.
What was sustained
At week 208, average weight change was −10.2% with semaglutide and −1.5% with placebo. Waist circumference changed by −7.7 cm and −1.3 cm. The report described weight loss continuing through approximately week 65 and then being sustained. Trial-product discontinuation was more frequent with semaglutide. [1]
A maintained average is not a claim that weight kept falling at the same speed for four years. It is also not proof that every participant remained on treatment or followed the average curve. A longer group trajectory adds useful information without becoming a template for an individual’s progress.
Why a smaller average does not invalidate other trials
If a number differs from a dedicated weight-management study, the first response should be to inspect design and population, not declare one result false. Different clinical settings and analysis choices can yield different averages while each accurately answers its own question.
It is particularly unhelpful to select whichever trial gives the largest figure for advertising and whichever gives the smallest for criticism. A balanced reading asks which population and treatment setting resemble the decision at hand. The comparator and follow-up period should stay attached to the result in either direction.
Waist change and weight change also tell different stories. A reduction in centimeters is not a percentage of starting weight, and neither measurement alone identifies the cause of cardiovascular benefit. The additional measurements broaden the description of the participants without proving a complete mechanism.
Translate duration into practical planning
Four-year evidence raises a useful consumer question: what does ongoing access look like beyond a short promotion? Ask about renewal, follow-up and how the service handles changes in coverage or pharmacy arrangements. Those terms cannot be inferred from a trial’s duration, but they affect whether a care plan is understandable.
Read the main SELECT cardiovascular analysis for the program’s principal endpoint. Our annual-cost article helps separate medication and membership assumptions. This weight analysis informs the time horizon of the discussion; it does not guarantee future cost, access or an individual long-term response.